BJH - volume 9, issue 5, september 2018
C. Bonnet MD, M.C. Ngirabacu , M. Maerevoet MD, V. De Wilde MD, PhD, E. Van den Neste MD, PhD, M. André MD, PhD
The 4th edition of the LYSA meeting was organised by Professor Steven Legouill’s team and held in Nantes from the 8th to 10th February, 2018. It was a real opportunity for the 500 participants to learn novelties on lymphoma and to be updated on ongoing clinical trials conducted by this cooperative group. All the presentations were outstanding and gave us new indications on how to better treat our patients in the near future.
(BELG J HEMATOL 2017;9(5):195–8)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
B. Stamatopoulos , T. Smith , E. Crompot , K. Pieters , R. Clifford , M. Mraz , P. Robbe , A. Burns , A. Timbs , D. Bruce , P. Hillmen , N. Meuleman MD, PhD, P. Mineur MD, R. Firescu , M. Maerevoet MD, V. De Wilde MD, PhD, A. Efira MD, J. Philippé MD, PhD, B. Verhasselt MD, PhD, F. Offner MD, PhD, A. Heger , D. Sims , H. Dreau , A. Schuh
BJH - 2018, issue Abstract Book BHS, february 2018
S. Dubruille PhD, C. Kenis , Y. Libert PhD, M. Delforge MD, PhD, L. Dal Lago , M. Roos , C. Borghgraef , A. Salaroli MD, M. Maerevoet MD, D. Razavi MD, PhD, H. Wildiers , D. Bron MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
C. Spilleboudt MD, F. Paciorkowski , M. Vercruyssen MD, L. Bienfait , M. Depierreux , M. Maerevoet MD, D. Bron MD, PhD, J. Nortier
BJH - 2018, issue Abstract Book BHS, february 2018
M. Maerevoet MD, P. Lewalle MD, PhD, N. Meuleman MD, PhD, C. Spilleboudt MD, A. Salaroli MD, S. Wittnebel MD, PhD
BJH - volume 8, issue 3, june 2017
D. Bron MD, PhD, C. Springael MD, PhD, M. Maerevoet MD, M. de Vicq MD, A. Kolivras MD
Cutaneous T-cell lymphoma is a heterogeneous group of T-cell neoplasms presenting in the skin, mycosis fungoides being the most common subtype and Sézary syndrome the leukemic form. Treatment is dependant on stage and responses to previous therapy. Treatments are divided into ‘skin-directed therapies’, which are first-line for early stage diseases, and ‘systemic therapies’ reserved for advanced stages or refractory cutaneous T-cell lymphoma. There are currently no curative therapies for cutaneous T-cell lymphoma and consecutive treatments have to be given in function of the progression of the disease. There is an urgent need for new therapies to treat symptoms, particularly pruritus and pain, and to prolong survival. This paper summarises new drugs available for cutaneous T-cell lymphoma and their mode of action. Most new drugs for cutaneous T-cell lymphoma have response rates between 30% and 50% with response durations being less than a year. New studies looking at combination or maintenance therapies may improve quality of life and disease outcome.
(BELG J HEMATOL 2017;8(3):102–6)
Read moreBJH - volume 8, issue Abstract Book BHS, february 2017
A. Pistone , M. Maerevoet MD, S. Wittnebel MD, PhD, M. Vercruyssen MD, S. Buntinx , C. Spilleboudt MD, D. Bron MD, PhD, N. Meuleman MD, PhD
Top
